Literature DB >> 18849011

Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.

Richard K Sterling1, Lennox Jeffers, Fredric Gordon, Alan P Venook, K Rajender Reddy, Shinji Satomura, Futoshi Kanke, Myron E Schwartz, Morris Sherman.   

Abstract

BACKGROUND & AIMS: Des-gamma-carboxy prothrombin (DCP) and Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) are surveillance markers used to detect hepatocellular carcinoma (HCC) in Japan. This study evaluated their utility, alone or in combination, in a North American population.
METHODS: Patients with hepatitis C virus-related cirrhosis were followed up prospectively for 2 years.
RESULTS: Of 372 patients, HCC developed in 34 of 298 who were free of HCC at entry. The overall sensitivity, specificity, and positive and negative predictive values for only AFP (>20 ng/mL) were 61%, 71%, 34%, and 88%, respectively; for only AFP-L3% (>10) were 37%, 92%, 52%, and 85%, respectively; and for only DCP (>7.5 ng/mL) were 39%, 90%, 48%, and 86%, respectively. Values increased when AFP values were combined with AFP-L3% and DCP to 77%, 59%, 32%, and 91%, respectively. Among patients with increases in AFP levels to 20 to 200 ng/mL, AFP-L3% and DCP were highly specific markers (86.6% and 90.2%, respectively). Of 29 HCC patients with AFP levels less than 20 ng/mL, 13 had increased levels of AFP-L3% or DCP. Increased alanine aminotransferase levels were associated with increased total AFP but not AFP-L3% or DCP levels. Both AFP-L3%- and DCP-positive patients showed significant differences in lower cumulative HCC-free rates compared with the overall group (P < .0001 and P = .0005, respectively).
CONCLUSIONS: AFP-L3% and DCP levels have higher correlation values with an absence of HCC, as well as a higher specificity and negative predictive value, than total AFP. Although this combination of markers only marginally improves surveillance for early HCC, it could identify individuals with negative imaging results who would benefit from follow-up evaluation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18849011     DOI: 10.1016/j.cgh.2008.08.041

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  46 in total

1.  Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.

Authors:  Richard K Sterling; Elizabeth C Wright; Timothy R Morgan; Leonard B Seeff; John C Hoefs; Adrian M Di Bisceglie; Jules L Dienstag; Anna S Lok
Journal:  Am J Gastroenterol       Date:  2011-09-20       Impact factor: 10.864

2.  Current status of alpha-fetoprotein testing.

Authors:  Morris Sherman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-02

3.  Limitations of screening for hepatocellular carcinoma.

Authors:  Morris Sherman
Journal:  Hepat Oncol       Date:  2014-03-20

Review 4.  Significant biomarkers for the management of hepatocellular carcinoma.

Authors:  Yasuteru Kondo; Osamu Kimura; Tooru Shimosegawa
Journal:  Clin J Gastroenterol       Date:  2015-04-09

5.  Semi-quantitative measurement of a specific glycoform using a DNA-tagged antibody and lectin affinity chromatography for glyco-biomarker development.

Authors:  Ju Hee Lee; Chang Hee Cho; Sun Hee Kim; Jeong Gu Kang; Jong Shin Yoo; Chulhun Ludgerus Chang; Jeong-Heon Ko; Yong-Sam Kim
Journal:  Mol Cell Proteomics       Date:  2014-12-18       Impact factor: 5.911

6.  Novel Lens culinaris agglutinin-reactive fraction of α-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α-fetoprotein concentrations.

Authors:  Manabu Morimoto; Kazushi Numata; Akito Nozaki; Masaaki Kondo; Satoshi Moriya; Masataka Taguri; Satoshi Morita; Miki Konno; Akie Sugo; Eiji Miyajima; Shin Maeda; Katsuaki Tanaka
Journal:  Int J Clin Oncol       Date:  2011-08-17       Impact factor: 3.402

Review 7.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.

Authors:  Alla Arzumanyan; Helena M G P V Reis; Mark A Feitelson
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

8.  Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma.

Authors:  Bal Krishan Sharma; Radhika Srinivasan; Shweta Kapil; Bhupesh Singla; Nitin Saini; Yogesh Kumar Chawla; Anuradha Chakraborti; Ajay Duseja; Naveen Kalra; Radha Krishan Dhiman
Journal:  Mol Cell Biochem       Date:  2013-08-04       Impact factor: 3.396

Review 9.  Biomarkers for the early diagnosis of hepatocellular carcinoma.

Authors:  Nobuhiro Tsuchiya; Yu Sawada; Itaru Endo; Keigo Saito; Yasushi Uemura; Tetsuya Nakatsura
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

10.  Current management of hepatocellular carcinoma.

Authors:  Ana Maria Crissien; Catherine Frenette
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.